期刊文献+

罗氟司特的合成 被引量:12

Synthesis of Roflumilast
原文传递
导出
摘要 3,4-二羟基苯甲醛与二氟一氯甲烷醚化得到3-羟基-4-二氟甲氧基苯甲醛,与氯甲基环丙烷醚化得到3-环丙基甲氧基-4-二氟甲氧基苯甲醛,再经氧化、氯代后与4-氨基-3,5-二氯吡啶反应,制得慢性阻塞性肺病治疗药罗氟司特,总收率约23%。 Roflumilast, an anti-chronic obstructive pulmonary disease (COPD) drug, was synthesized from 3,4- dihydroxybenzaldehyde via etherification with chlorodifluoromethane to give 3-hydroxy-4-difluoromethoxybenzaldehyde, which was subjected to etherification with chloromethylcyclopropane to give 3-eyclopropylmethoxy-4-difluoro- methoxybenzaldehyde, followed by oxidation, chlorination and then reaction with 4-amino-3,5-dichloropyridine with an overall yield of about 23 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2011年第12期884-886,共3页 Chinese Journal of Pharmaceuticals
关键词 罗氟司特 慢性阻塞性肺病 合成 roflumilast chronic obstructive pulmonary disease synthesis
  • 相关文献

参考文献10

  • 1冯波.第二代PDE4抑制剂Roflumilast[J].药学进展,2002,26(2):121-122. 被引量:7
  • 2冯桂山,宋宁,段争,吴雅莉.罗氟司特治疗慢性阻塞性肺疾病药理作用的临床前研究现况[J].临床荟萃,2011,26(4):363-366. 被引量:20
  • 3Bose P, Sachdeva YP, Rathore RS, et al. Process for the preparation of roflumilast: WO, 2005 026095 [P-. 2005-03-24. (CA 2005, 142: 336129).
  • 4Palle VP, Balachandran S, Salman M, et al. lnhibitors ofphosphodiesterasetype-lV: WO, 2005021515 [P]. 2005-03-10. (CA 2005, 142: 298095).
  • 5Gharat LA, Gajera JM, Patil SD, et al. Novel processes for preparing 6- (difluoromethoxy) [ 1 ] benzofuro [3,2- c] pyridine-9-carboxaldehyde, a novel intermediate for the systhesis of PDE IV inhibitors: WO, 2008142542 [P]. 2008-11-27. (CA2008, 150: 5710).
  • 6Amari G, Armani E, Villetti G. Ester derivatives as phosphodiesterase inhibitors: WO, 2009077068 [P]. 2009-06-25. (CA 2009, 151: 77927).
  • 7Amari G, Armani E, Ghidini E. Derivatives of 1-phenyl-2- pyridinyl alkylene alcohols as phosphodiesterase inhibitors: WO, 2008006509 [P]. 2008-01-17. (CA 2008, 148: 168589).
  • 8Kelly DJ, Williams S J, Zammit S. Halogenated analogues of anti-fibrotic agents and their preparation: WO, 2009079692 [P]. 2009-07-02. (CA2009, 151: 100915).
  • 9Amschler H, Flockerzi D, Gutterer B, et al. Fluoroalkoxysubstituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors: WO, 9501338 [P]. 1995-01-12. (CA 1995, 122: 239550).
  • 10Duplantier A J, Eggler JF, Marfat A, et al. Catechol diethers as selective PDEIV inhibitors: WO, 9412461 [P]. 1994-06-09. (CA 1994, 121: 255405).

二级参考文献29

  • 1World Health Organization. World health statistics 2008[S].Geneva,Switzerland : World Health Organization, 2008.
  • 2Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities[J]. Proc Am Thorac Soc,2008,5(8) :857-864.
  • 3Giembycz MA,Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD[J]. Drug Des Devel Ther, 2010,21 (4) : 147-158.
  • 4Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast-a selective,oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther,2010,23(4) :235-256.
  • 5Hardaker EL,Freeman MS,Dale N, et al. Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung[J]. Br J Pharmacol,2010,160(8) : 1985-1996.
  • 6Le Quement C,Guenon I,Gillon JY,et al. The selective MMP- 12 inhibitor, ASl11793 reduces airway inflammation in mice exposed to cigarette smoke[J]. Br J Pharmacol, 2008,154 (6) 1206-1215.
  • 7Martorana PA,Beume R, Lueattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke[J]. Am J Respir Crit Care Meal,2005,172(7):848-853.
  • 8Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin induced lung injury[J]. Br J Pharmacol,2009,156(3) :534- 544.
  • 9Grootendorst DC,Gauw SA,Verhoosel RM,et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD[J]. Thorax,2007, 62(12) :1081-1087.
  • 10Hohlfeld JM, Schoenfeld Roflumilast attenuates K, Lavae-Mokhtari M, et al. pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial[J]. Pulm Pharmacol Ther, 2008,21(4) :616- 623.

共引文献22

同被引文献71

  • 1张虞安,胡卓逸,赵烨,蔡惠民.苄基异喹啉类化合物 D_(20)抑制钙调素激活磷酸二酯酶的研究[J].生物化学与生物物理进展,1993,20(1):28-32. 被引量:1
  • 2楚刚辉,陈璐,程靖.非水滴定法测定阔草清含量的研究[J].现代农药,2007,6(4):42-44. 被引量:5
  • 3AMARI G, ARMANI E, GHIDINI E. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodi- esterase inhibitors : WO, 2008006509 [P]. 2008 - 01 -17.
  • 4LOHRAY B B,LOHRAY V B, DAVE M G. Prepa- ration of roflumilast and its analogs: IN, 2004MU00478 [ P]. 2007 - 10 - 12.
  • 5GAVHANE S B, WAKADE S M, KADAM S M. Novel process for the preparation of 3-( cyclopropyl- methoxy ) -N-( 3, 5-dichloropyridin-4-yl ) -4-( diflu- oromethoxy) benzamide: WO, 2012147098 [ P ]. 2012-11 -01.
  • 6王一茜,戚太林,刘威加.一种罗氟斯特原料及中间体的制备方法:中国,102532011[P].2012-01-05.
  • 7WILLIAMS E L, WU T C. Process for production of fluoroalkoxy-substituted benzamides and their inter- mediates: WO,2004033430 [ P ]. 2004 - 04 - 22.
  • 8廖明毅,李瑞,杨少宁,等.3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成新方法:中国,102093194[P].2011-06-15.
  • 9严洁,黄欣.高生物利用度的罗氟司特化合物:中国.102351787[P].2012-02-15.
  • 10BOSE P, SACHDEVA Y P, RATHORE R S, et al. Process foe the preparation of roflumilast: WO, 2005026095 [ P ]. 2005 - 03 - 24.

引证文献12

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部